Form 4: Belite Bio CEO Sells Shares Under 10b5-1 Plan

Belite Bio CEO Lin Yu-Hsin has sold a total of 8,700 American depositary shares under a pre-arranged trading plan, generating proceeds of approximately $1.58 million.

Summary

• Lin Yu-Hsin, CEO of Belite Bio, Inc. (BLTE), reported the sale of 8,700 American depositary shares (ADS) on April 9, 2026.
• These sales were executed under a Rule 10b5-1 trading plan adopted on December 23, 2025.
• The total value of the shares sold is approximately $1.58 million, with individual sale prices ranging from $180.00 to $183.00 per ADS.
• Following these transactions, Lin Yu-Hsin beneficially owns 170,934 ADS.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a slightly negative sentiment due to significant insider selling, despite the use of a 10b5-1 plan. The substantial value of shares sold by the CEO warrants attention.

Positives

• The sales were conducted under a Rule 10b5-1 plan, indicating pre-planned and potentially less market-impacting transactions.
• The CEO continues to hold a significant number of shares (170,934 ADS) after the sales.

Negatives

• A significant number of shares were sold by the CEO, which could be perceived negatively by the market.
• The total value of shares sold is substantial, amounting to approximately $1.58 million.

Risks

• Potential for negative market perception due to insider selling, even if conducted under a 10b5-1 plan.
• The specific reasons for the sales are not detailed, which could lead to speculation.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future company performance. It solely reports on past transactions by an insider.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/23/2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, is a common event for executives and directors. While it can sometimes signal a lack of confidence, it is often part of a pre-determined diversification or liquidity strategy. The context of Belite Bio's current market position and recent performance would be crucial for a complete assessment.

Stakeholder Impact

• Shareholders may view the CEO's sale of a significant number of shares with concern, potentially impacting short-term stock price sentiment.
• Employees with stock options or grants may be influenced by the CEO's actions, though the 10b5-1 plan mitigates concerns about non-public information.

Next Steps

• Monitor future SEC filings for any further transactions by Lin Yu-Hsin or other insiders.
• Analyze the company's upcoming financial reports and strategic updates for context regarding the CEO's share sales.

Key Dates

Recommendation

The filing reports insider selling under a pre-arranged plan, which is a common practice for executives. While it can create short-term negative sentiment, it does not inherently signal a fundamental change in the company's prospects. A 'hold' recommendation is appropriate pending further analysis of the company's operational performance and strategic developments.

Keywords

Belite Bio, BLTE, Form 4, Insider Trading, Stock Sale, CEO, Lin Yu-Hsin, Rule 10b5-1, American Depositary Shares, SEC Filing